Melanotan II (MT2)

Melanotan 2 Peptide

Melanotan II (MT-II) is a laboratory-synthesized, cyclic heptapeptide that acts as a potent analog of the natural alpha-melanocyte-stimulating hormone (alpha-MSH). This synthetic peptide possesses a selective binding profile, functioning as an agonist for multiple melanocortin receptor (MCR) subtypes, with high affinity for MC4R and MC1R. While initially researched for stimulating melanogenesis (melanin production) for skin pigmentation, its primary current research applications focus on its centralized effects on appetite control, sexual function, and various neurobiological pathways.

Melanotan 2 Peptide Overview

Melanotan II (MT-II) is a powerful synthetic alpha-MSH analogue originating from research conducted at the University of Arizona during the 1980s. The development was spurred by the discovery that the endogenous alpha-MSH influenced not only pigmentation but also behavioral and physiological responses in animal models.

Though originally conceived as a means to promote skin pigmentation without UV exposure, MT-II's extensive range of biological activities soon became the primary focus. Current scientific studies explore its influence on metabolic regulation, sexual health, and appetite suppression. Preliminary findings suggest roles in areas such as glucagon control, appetite suppression, and the modulation of compulsive behaviors, though these effects are subject to ongoing investigation and are not clinically approved.

Melanotan 2 Peptide Structure

MT-II is a synthetic molecule known as a cyclic heptapeptide. This structure, a sequence of seven amino acids arranged in a ring, grants the peptide enhanced stability and allows for specific, potent activation of melanocortin receptors, especially MC1R and MC4R.

Melanotan 2 Peptide Research

Melanotan II and Melanocortin Signaling

Melanotan II (MT-II) exerts its biological functions by acting as an agonist on the Melanocortin Receptor (MCR) family. This family comprises five distinct subtypes (MC1R–MC5R). MT-II demonstrates the highest binding affinity for MC4R and MC1R, and measurable affinity for MC3R. This varied receptor activation is responsible for the peptide’s broad systemic effects, as these receptors are distributed across different tissues.

MCR Subtype

Primary Function

Relevance to MT-II Research

MC1R

Pigmentation; Melanin synthesis

Target for skin darkening studies.

MC2R

Glucocorticoid release

Involved in stress and adrenal function.

MC3R

Appetite and energy balance

Explored in metabolic regulation.

MC4R

Feeding, Sexual function, Arousal

Key target for appetite suppression and sexual function.

MC5R

Exocrine secretion

Studied in relation to glandular and metabolic function.

Melanotan II and Autism

Emerging research has explored the therapeutic potential of Melanotan II (MT-II) in models of Autism Spectrum Disorder (ASD). Experimental data from the maternal immune activation (MIA) mouse model of ASD suggests MT-II administration may alleviate certain autistic-like traits. The rationale for this research is the known therapeutic effect of oxytocin in improving social and behavioral deficits in ASD.

In the MIA mouse model, MT-II, which is known to enhance oxytocin secretion, was found to reverse several core ASD symptoms, including reduced social interaction, impaired communication, and repetitive behavior patterns.

The study further indicated that MT-II significantly upregulated oxytocin receptor expression in critical brain regions for social cognition. These findings suggest MT-II could modulate neuroendocrine pathways relevant to social behavior and developmental neurodisorders.

Melanotan 2 and Hunger

Evidence from animal studies indicates that MT-II can suppress hunger and reduce fat accumulation. As a powerful activator of the melanocortin-4 receptor (MC4R), MT-II is crucial in regulating food intake. In mice, MT-II not only reduces overall food consumption but also induces a strong aversion to high-fat foods, an effect dependent on the MC4R receptor.

The action of MT-II is compared to the satiety hormone leptin. However, while leptin's effectiveness against obesity is limited, MT-II is hypothesized to activate both leptin-dependent and leptin-independent satiety pathways. Furthermore, MT-II influences the expression of thyrotropin-releasing hormone (TRH), linking it to central satiety pathways.

Melanotan 2 and Diabetes

MT-II is researched in the context of diabetes due to its ability to mimic leptin's anti-diabetic effects: reducing high blood glucose, limiting glucagon, and inhibiting ketone production, all independent of insulin. Since these effects are melanocortin receptor-mediated, MT-II demonstrates comparable regulatory effects.

A key pharmacological advantage of MT-II is its superior ability to cross the blood-brain barrier compared to external leptin. This greater central nervous system accessibility allows MT-II to more effectively engage the melanocortin pathways involved in metabolic regulation.

Melanotan 2, Impulse Control, and Alcohol Intake

The MC4R receptor is critically involved in regulating impulse control. Experimental studies in rats show that MT-II administration decreases alcohol consumption while increasing water intake. New research also demonstrates a strong synergistic effect with naltrexone, significantly boosting naltrexone’s efficacy in reducing binge-like ethanol intake in mice.

These results suggest MT-II could be an important tool for investigating the neurobiological basis of craving and desire, potentially leading to new therapies for alcohol-related disorders and other impulsive behaviors.

Melanotan 2 and Erectile Dysfunction

Unlike traditional ED treatments that target vascular issues, MT-II has been shown to be effective through its action on the central nervous system pathways. This central mechanism provides a benefit for non-vascular causes of ED. Clinical studies indicated that approximately 80% of men unresponsive to Viagra experienced improvement with MT-II treatment. Research is ongoing regarding its potential for both male and female sexual desire disorders.

Article Author

This literature review was compiled, written, and organized by Dr. Mac E. Hadley, Ph.D., a renowned authority in melanocortin peptide pharmacology. Dr. Hadley is famous for the seminal discovery that melanocortin peptides influence sexual function in both men and women, which significantly spurred clinical interest in Melanotan II. His foundational work at the University of Arizona was key to advancing the scientific understanding of melanocortin receptor biology and the therapeutic potential of peptide analogs.

Scientific Journal Author

Dr. Mac E. Hadley collaborated closely with other leading researchers, including Dr. Victor J. Hruby, Dr. H. Wessells, and Dr. Stephen H. King. Their combined studies were instrumental in deepening the pharmacological knowledge of Melanotan II. Their publications in major scientific journals clarified the peptide's receptor selectivity, molecular function, and clinical relevance as a melanocortin receptor agonist, establishing the scientific foundation for MT-II's diverse effects.

Reference Citations

• Ryakhovsky, Vladimir V et al. "The first preparative solution phase synthesis of Melanotan II." Beilstein Journal of Organic Chemistry vol. 4 (2008): 39. doi:10.3762/bjoc.4.39. https://pubmed.ncbi.nlm.nih.gov/19043625/
• Hadley, Mac E. "Discovery that a melanocortin regulates sexual functions in male and female humans." Peptides, Volume 26, Issue 10, 2005, Pages 1687-1689. https://doi.org/10.1016/j.peptides.2005.01.023
• King, Stephen H et al. "Melanocortin receptors, melanotropic peptides and penile erection." Current topics in medicinal chemistry vol. 7,11 (2007): 1098-1106. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694735/
• Peters, Björn, et al. "Melanotan II: a possible cause of renal infarction: review of the literature and case report." CEN case reports vol. 9,2 (2020): 159-161. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7148395/
• Ter Laak, Mariël P, et al. "The potent melanocortin receptor agonist melanotan-Il promotes peripheral nerve regeneration and has neuroprotective properties in the rat." European Journal of Pharmacology vol. 462,1-3 (2003): 179-83. https://pubmed.ncbi.nlm.nih.gov/12591111/
• Wessells, H et al. "Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II." International journal of impotence research vol. 12 Suppl 4 (2000): S74-9. https://pubmed.ncbi.nlm.nih.gov/11035391/
• Minakova E, Lang J, Medel-Matus JS, Gould GG, Reynolds A, Shin D, Mazarati A, Sankar R. "Melanotan-Il reverses autistic features in a maternal immune activation mouse model of autism." PLoS One. 2019 Jan 10;14(1):e0210389. doi: 10.1371/journal.pone.0210389. https://pubmed.ncbi.nlm.nih.gov/30629642/
• Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. "Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study." Life Sci. 1996;58(20):1777-84. https://pubmed.ncbi.nlm.nih.gov/8637402/

Important Research Disclaimer

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: "in glass") are experiments conducted outside of a living organism. These products are not classified as medicines or drugs and have not been approved by the FDA or any regulatory body to prevent, treat or cure any medical condition, ailment, or disease. Introduction of any kind into humans or animals is strictly forbidden by law.

Storage

Storage Instructions

All products are prepared via a lyophilization (freeze-drying) process, which ensures stability during shipping for approximately 3–4 months.

• Lyophilized Peptides (Powder): The stable, white crystalline powder is safe for storage at room temperature for several weeks. For short-term use (days, weeks, or months), refrigeration below 4 degrees C (39 degrees F) is sufficient. For extended storage (months to years), freezing at -80 degrees C (-112 degrees F) is highly recommended to maintain structural integrity.
• Reconstituted Peptides (Solution): Once mixed with bacteriostatic water, the peptide solution must be stored in a refrigerator (below 4 degrees C). Reconstituted peptides are typically stable for up to 30 days.

Best Practices For Storing Peptides

Proper storage protocols are essential for maintaining the accuracy and reliability of laboratory results by minimizing contamination, oxidation, and degradation.

Storage Condition

Peptide Form

Recommended Temperature

Maximum Stability Duration

Short-Term

Lyophilized or Reconstituted

Below 4 degrees C (Refrigerated)

Up to a few months (Lyophilized); Up to 30 days (Reconstituted)

Long-Term

Lyophilized

-80 degrees C (Frozen)

Several months to years

Preventing Oxidation and Moisture Contamination

Protecting peptides from exposure to air and moisture is critical for stability.

• Moisture Control: Always allow the vial to reach room temperature before opening after removal from the freezer to prevent condensation from contaminating the powder.
• Air Exposure: Minimize the time the container is open. Promptly reseal the container. Storing the remaining peptide under a dry, inert gas (e.g., nitrogen or argon) can help prevent oxidation. Peptides containing cysteine (C), methionine (M), or tryptophan (W) residues are especially sensitive to oxidation.
• Handling: To maintain long-term stability, avoid frequent thawing and refreezing. Divide the total peptide into smaller aliquots for single-use experiments.

Storing Peptides In Solution

Peptide solutions have a significantly shorter shelf life and are more prone to degradation than lyophilized forms.

• Degradation Risk: Peptides with residues like Cysteine, Methionine, Tryptophan, Aspartic acid, Glutamine, or N-terminal Glutamic acid degrade more rapidly in solution.
• Guidelines: If liquid storage is unavoidable, use sterile buffers with a pH between 5 and 6. Aliquots should be prepared to minimize freeze-thaw cycles. Most peptide solutions remain stable for up to 30 days when refrigerated at 4 degrees C.

Peptide Storage Containers

Containers must be clean, durable, and chemically resistant, and appropriately sized to minimize air space. Glass vials offer the best combination of clarity, stability, and chemical inertness. Plastic vials are also suitable.

Peptide Storage Guidelines: General Tips

Adhere to these best practices for optimal peptide stability:

• Store peptides in a cold, dry, and dark environment.
• Avoid repeated freeze-thaw cycles.
• Minimize exposure to air and light.
• Keep peptides lyophilized for long-term storage whenever possible.
• Aliquot the peptide based on experimental needs.